



American Society of Clinical Oncology

Since the publication of the *2009 ASCO Annual Meeting Proceedings Part I*, a supplement to the May 20 issue of the *Journal of Clinical Oncology*, ASCO has become aware of several errors in the printed content. All errors have been corrected in the online versions of the abstracts. A list of changes is also provided below. ASCO regrets the errors.

Disclosure information for abstracts 10008b and 10048 was not included in the print version of the 2009 Abstract Disclosure Index. For both abstracts, authors reported no significant financial relationships to disclose.

In abstracts 4580, 4590, and 8006, data values were missing from the tables. Corrected tables are shown in their entirety below.

Abstract 4580

Group	n		OS (sorafenib/placebo)		DCR (%)
	Sorafenib	Placebo	Median (mo)	HR (95% CI)	(sorafenib/placebo)
SHARP					
Overall	299	303	10.7/7.9	0.69 (0.55, 0.87)	43.5/31.7
MVI/EHS	209	212	8.9/6.7	0.77 (0.60, 0.99)	41.2/27.8
No MVI/EHS	90	91	14.5/10.2	0.52 (0.32, 0.85)	48.9/40.7
ECOG 0	161	164	13.3/8.8	0.68 (0.50, 0.95)	46.6/36.0
ECOG 1/2	138	139	8.9/5.6	0.71 (0.52, 0.96)	39.9/26.6
AP					
Overall	150	76	6.5/4.2	0.68 (0.50, 0.93)	35.3/15.8
MVI/EHS	118	61	5.6/4.1	0.75 (0.54, 1.05)	30.5/11.5
No MVI/EHS	32	15	14.3/8.0	0.45 (0.19, 1.06)	53.1/33.3
ECOG 0	38	21	7.1/8.1	0.77 (0.42, 1.44)	39.5/23.8
ECOG 1/2	112	55	6.1/3.9	0.61 (0.42, 0.88)	33.9/12.7

Abstract 4590

Population	n		TTP (sorafenib/placebo)		OS (sorafenib/placebo)		DCR (%) (sorafenib/ placebo)
	Sorafenib	Placebo	Median	HR	Median	HR	
			(mo)	(95% CI)	(mo)	(95% CI)	
Total	150	76	2.8/1.4	0.57 (0.42, 0.79)	6.5/4.2	0.68 (0.50, 0.93)	35.3/15.8
Normal ALT/AST (<1.8x ULN)	86	46	2.9/1.5	0.63 (0.42, 0.96)	8.2/8.0	0.76 (0.50, 1.16)	39.5/21.7
Mildly elevated ALT/AST (1.8-3.0x ULN)	33	18	2.1/1.2	0.41 (0.21, 0.78)	4.9/3.1	0.57 (0.31, 1.08)	33.3/11.1
Moderately elevated ALT/AST (>3.0x ULN)	31	12	2.7/1.3	0.31 (0.12, 0.81)	5.0/2.0	0.32 (0.15, 0.68)	25.8/0.0
Normal AFP (≤40 µg/L)	28	22	2.9/2.8	0.63 (0.33, 1.22)	11.0/6.4	0.59 (0.29, 1.20)	42.9/31.8
Elevated AFP (>40 µg/L)	114	54	2.8/1.3	0.48 (0.33, 0.71)	5.9/4.1	0.65 (0.45, 0.93)	35.1/9.3

Abstract 8006

EGFR	n	PFS HR G:CP	PFS 95% CI	PFS p value	PFS treatment by biomarker interaction test		ORR % G/CP	ORR OR G:CP	ORR 95% CI	ORR p value
					p-value (HR in + vs HR in -)					
M +	261	0.48	0.36- 0.64	<0.0001	<0.0001		71.2/47.3	2.75	1.65- 4.60	0.0001
M -	176	2.85	2.05- 3.98	<0.0001			1.1/23.5	0.04	0.01- 0.27	0.0013
M Unknown	780	0.68	0.58- 0.81	<0.0001			43.3/29.2	1.88	1.39- 2.53	<0.0001
FISH +	249	0.66	0.50- 0.88	0.0050	0.0437		58.9/44.8	1.79	1.08- 2.96	0.0243
FISH -	157	1.24	0.87- 1.76	0.2368			22.2/26.3	0.80	0.38- 1.68	0.5580
FISH Unknown	811	0.70	0.60- 0.83	<0.0001			42.3/29.5	1.76	1.32- 2.37	0.0002
PE +	266	0.73	0.55- 0.96	0.0243	0.2135		51.5/41.8	1.49	0.92- 2.42	0.1093
PE -	99	0.97	0.64- 1.48	0.8932			34.0/26.1	1.44	0.60- 3.47	0.4146
PE Unknown	852	0.73	0.62- 0.85	<0.0001			41.5/29.9	1.66	1.25- 2.22	0.0005